NCT03866499 - A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients | Biotech Hunter

Enrollment

369

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

December 30, 2025

Conditions

NSCLC

Interventions

DRUG

BPI-7711

180 mg, oral, QD

DRUG

Gefitinib

250 mg, oral, QD

DRUG

Placebo Tablet

250 mg gefitinib placebo tablet, QD

DRUG

Placebo capsule

180 mg BPI-7711 placebo capsule, QD

Trial Locations (3)

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Linyi Cancer Hospital, Linyi